Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
| Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
|---|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 | 0 |
| % | 0 | 0 | 0 | 0 | 0 |
The Captial Market (CapitalMarket.com) rating for Valiant Laboratories IPO is 37. Their analysis recommends Do Not Subscribe for the IPO.
| Reviewer | Rating Score | Rating |
|---|---|---|
| Capital Market | 37 | Do Not Subscribe |
[Dilip Davda] The company is in the business of manufacturing APIs and bulk drugs with a prime focus on widely used paracetamol. However, the company has posted declining trends for its PAT and RoCE margins for the reported periods. Based on FY23 earnings, the issue appears fully priced. Investors may park funds for medium to long-term rewards. Read detail review...
Valiant Laboratories Limited peer comparison with similar listed entities. (Standalone) (As on March 31, 2023)
| Company Name | EPS (Rs) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | |
|---|---|---|---|---|---|
| EPS Basic | EPS Diluted | ||||
| Valiant Laboratories Limited | 8.91 | 8.91 | 30.80 | 28.86 | |
| Granules India Ltd | 21.05 | 21.00 | 115.52 | 15.06 | 18.22 |
| Jagsonpal Pharmaceuticals Limited | 10.20 | 10.20 | 6.06 | 41.54 | 16.82 |
| Alkyl Amines Chemicals Ltd | 44.75 | 44.68 | 228.41 | 55.59 | 19.56 |
| Laxmi Organic Industries Limited | 4.70 | 4.67 | 52.89 | 66.07 | 8.83 |
Notes:
Valiant Laboratories IPO Reviews, analysis and views by popular members. Read Valiant Laboratories Ltd. IPO reviews by retail investors to find recommended ipo to buy.
| Review By | Apply | May Apply | Neutral | Avoid |
|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 |
| % | 0.00 | 0.00 | 0.00 | 0.00 |
| Member | Review |
|---|---|
| No recommendation found. Be the first to post the recommendation. | |
Note:
Useful Articles
RHP